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Sir,
We would like to thank Antinori et al.1 for their comments on the
European Conference on Infections in Leukemia (ECIL) guidelines
for the management of Pneumocystis jirovecii pneumonia (PCP).2
Antinori et al.1 listed four points, which we would like to address
one by one.
Mode of acquisition of PCP in haematology patients
The mode of acquisition of PCP in haematology patients is uncertain, but
there is no reason to think that it is different from that in other immunocom-
promised patients. Exposure to P. jirovecii through inhalation begins early in
life, as shown by autopsy series, and PCR and serological screenings.3–6 The
high rate of mixtures of genotypes during PCP (up to 90%) also supports con-
tinuous exposure to P. jirovecii from the environment via other humans.7
When investigating outbreaks in solid organ transplant units using genotyp-
ing, only some of the cases were shown to be due to inter-human or environ-
mental transmission.8,9 To our knowledge, only two outbreaks have been
reported in haematology wards. The first one included five cases in 6 months
in the same haematology unit, but without any molecular investigation.10
The second study established a genetic link using internal transcribed spacer
(ITS) sequencing between the strains for two out of eight haematology pa-
tients (and two out of six HIV-positive patients), suggesting that person-to-
person transmission was relatively infrequent.11 Recently, transmission be-
tween patients from different wards was reported with the help of six new
short tandem repeat markers located in the nuclear genome.12 However,
even with this highly discriminant genotyping method, we could not differen-
tiate between reactivation and a new infection.12 Despite the lack of solid
data reflected by a grading of only C-III, ECIL proposed that patients in
haematology should, nonetheless, avoid contact with those infected with
PCP.13
Differences in clinical presentation and hypoxaemia
between patients with and without HIV infection
Antorini et al.1 show that two-thirds of their patients with HIV infection had a
PaO2 ,70 mmHg. However, the PaO2 of patients with PCP, but without HIV in-
fection, was not presented. This makes any conclusion about PaO2 at diagno-
sis difficult. We agree with Antorini et al.1 that PaO2 at presentation can be
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highly dependent on the quality of local care, especially rapid access to bron-
choalveolar lavage. Indeed, the delay from the onset of symptoms to estab-
lishing a diagnosis of PCP was variable according to the year of diagnosis and
the centres involved and may well have had an impact on the severity at
presentation.14–19 Nevertheless, apart from open studies reporting high rates
of hypoxaemia in patients with PCP and underlying haematological condi-
tions, parallel comparisons of those with and without HIV infection showed
that the degree of respiratory failure at presentation (often before admission
to the ICU), whether assessed by PaO2, SatO2 or PaO2/FiO2, was significantly
higher in those without HIV infection15–17,20 and the need for ventilation was
significantly more frequent in three series,14,17,19 but not in a fourth one.18 A
recent French series, which was not available at the ECIL-5 meeting, confirms
this pattern since only 25 (11%) of 223 patients with AIDS required invasive
mechanical ventilation, compared with 98 (30.5%) of 321 with another
underlying condition, including 111 with haematological diseases.19
Moreover, a diagnosis of AIDS was associated with lower mortality, whereas
the converse was true for receipt of an allogenic HSCT and the need for mech-
anical ventilation.19
Lactate dehydrogenase (LDH) levels at presentation
LDH levels at diagnosis were 39%–46% higher among patients with HIV in-
fection than among those without.14,18,21 However, the ECIL-5 laboratory
diagnosis group concluded that this discussion had been superseded by the
ready availability of more specific laboratory tools, such as PCR or b-D-glu-
can detection, making further mention of LDH elevation for the diagnosis of
PCP redundant.22 We consider, however, that an unexplained serum LDH
elevation in the presence of a suggestive clinical presentation could be
taken into account when deciding upon initiation of PCP treatment, provid-
ing quick, direct investigations.23
Mortality rates in HIV-positive patients
The mortality due to PCP is usually assessed at day 90 after onset. In series
of patients with HIV infection reported from 2000s, it was reported to vary
from 9.6%17 to 30%.18,20 By contrast, a recent French survey reported an
in-hospital mortality rate of 4% for those with AIDS, which was significantly
lower than the 27% rate found for those with other underlying
conditions.19
Besides the higher mortality, PCP in those not infected with HIV tends to
occur very abruptly and carries a high risk of ICU transfer. Hence, the
haematology community should be alerted to this possibility and needs to
ensure adequate and timely diagnostic and prevention strategies are de-
veloped and implemented to offer the best outcomes.
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